CDNs have also been evaluated with a number of other cancer antigens and cancer vaccines, including MUC1 glycopeptide [147], a B16 melanoma peptide [148], and a mouse model of glioma [70] and EG7-Ova tumour [57]. The gene discussed is MUC1; the disease is cancer.